Additionally, many effectively founded adverse prognostic markers, such as U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, missing their destructive impact in clients addressed with VO. The only issue that remained predictive of the shorter development-no cost survival in this cohort of patients w